Enovis Corporation

ENOV · NYSE · Stock · Healthcare
$18.57
-2.21% today
Delayed price,

What Enovis does

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$1.07B
P/E (ttm)
—
Forward P/E
5.2
Dividend yield
0.00%
Beta
1.48
Profit margin
-48.0%
Employees
7,802
Headquarters
Lewisville, TX, United States
Exchange
NYSE

Performance

1 Month
+2.9%
3 Months
-31.4%
6 Months
-29.4%
1 Year
-40.9%
5 Years
-76.8%
$16.7052-week range$34.28
Biggest setback — last 12 months
-46.2%
20 Oct 2025 → 5 Oct 2026
Fell from $32.87 to $17.69 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+33.9%
9 Feb 2026 → 27 Jul 2026
Ran from $21.77 to $29.15 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Below long-term trend
Price sits below its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$15.39 (-17.1%)$18.57$22.41 (+20.7%)
3 Months$13.41 (-27.8%)$18.57$25.71 (+38.4%)
6 Months$11.72 (-36.9%)$18.57$29.42 (+58.4%)
12 Months$9.69 (-47.8%)$18.57$35.59 (+91.7%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 65.1%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Acquired 958 shares — Ortiz Christine, Director · 2026-10-01
Acquired 2,660 shares at $18.80 — Engert Oliver, Chief Administrative Officer · 2026-09-08
Acquired 7,598 shares at $19.46 — Engert Oliver, Chief Administrative Officer · 2026-09-04
Acquired 13,035 shares at $19.15 — McDonald Damien, Chief Executive Officer · 2026-09-04
Acquired 846 shares — Ortiz Christine, Director · 2026-07-01
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.